Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Venous Thromboembolism 6Venous Thrombosis 5Neoplasms 5Pulmonary Embolism 4Neoplasm Metastasis 2Intracranial Thrombosis 2Thrombosis 1Thromboprophylaxis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Mesenteric Ischemia 1Lymphoma 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 60Vincristine 57Doxorubicin 54Rituximab 48Prednisone 44Etoposide 35Radiotherapy 34Cytarabine 26Filgrastim 22Methotrexate 21Bleomycin 21Dexamethasone 18Peripheral Blood Stem Cell Transplantation 14Carmustine 14Vinblastine 13Prednisolone 13VAP-cyclo protocol 12Melphalan 12Mitoxantrone 11Mercaptopurine 10Leucovorin 10Dacarbazine 9Ifosfamide 8Granulocyte Colony-Stimulating Factor 8Procarbazine 7Methylprednisolone 7Lenalidomide 7Gemcitabine 7Daunorubicin 7Cisplatin 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma × apixaban × Clear all
NCT02369653 2022-03-08

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

Bristol-Myers Squibb

Phase 3 Completed
512 enrolled 26 charts
LymphoidOther hematologic neoplasm

Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡